Form 4: Immix Biopharma Director Magda Marquet Reports New Stock Option Grant and Updated Beneficial Ownership

Immix Biopharma, Inc. Director Magda Marquet has reported the acquisition of 33,000 stock options and updated her beneficial ownership of common stock, as detailed in a recent SEC Form 4 filing.

Summary

• Magda Marquet, a Director of Immix Biopharma, Inc. (IMMX), filed a Form 4 with the SEC.
• The filing reports changes in her beneficial ownership of Immix Biopharma securities.
• On June 20, 2025, Ms. Marquet was granted 33,000 stock options.
• These options have an exercise price of $2.24 per share and are set to expire on June 20, 2035.
• The stock options will vest in twelve equal monthly installments following the grant date, contingent on Ms. Marquet's continued service with the Issuer.
• Following the reported transactions, Ms. Marquet directly owns 46,092 shares of common stock.
• She also indirectly owns 20,000 shares of common stock via ALMA Life Sciences, LLC.
• Additionally, she directly holds 33,000 stock options.

Sentiment

Score: 6

Explanation: The document is a routine insider transaction report (Form 4). The grant of stock options to a director is generally a positive sign of alignment between management and shareholder interests, but it does not contain significant new operational or financial news to warrant a high score. It's a neutral to slightly positive administrative filing.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule over twelve equal monthly installments encourages the director's continued service and commitment to the company.

Future Outlook

The stock option grant includes a vesting schedule over twelve equal monthly installments, indicating an expectation of continued service from the reporting person and aligning her incentives with the company's long-term performance and strategic goals.

Management Comments

• The filing was signed by Ilya Rachman as Attorney-In-Fact for Magda Marquet, referencing a Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions within the biotechnology and pharmaceutical industry, reflecting standard compensation practices for directors. Equity grants are a common mechanism to align the interests of company leadership with those of shareholders, fostering long-term growth and stability in the highly competitive biopharma sector.

Comparison to Industry Standards

• The grant of stock options to a director is a common and widely accepted practice in the biopharma industry, serving as a key component of executive and director compensation packages.
• Such equity grants are standard across publicly traded biotech firms to attract, retain, and incentivize top talent by linking their personal financial success to the company's stock performance.
• The exercise price of $2.24 for the options is typically set at or above the market price on the grant date, which is a standard industry practice for incentive stock options.

Related Party Transactions

• Magda Marquet holds 20,000 shares of common stock indirectly via ALMA Life Sciences, LLC, indicating a beneficial ownership interest through a related entity.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially fostering long-term value creation and improved corporate governance.
• Employees: The vesting schedule for the options is contingent on continued service, which can contribute to management stability and retention.

Next Steps

• The 33,000 stock options will continue to vest in twelve equal monthly installments from June 20, 2025, subject to the reporting person's continued service.
• Magda Marquet may exercise the vested stock options at or after their respective vesting dates.

Key Dates

Recommendation

Keywords

Immix Biopharma, IMMX, Magda Marquet, SEC Form 4, Beneficial Ownership, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Biopharma